Jubilant Pharmova Ltd

Securities in F&O Ban: Aditya Birla Fashion & Retail (ABFRL), Birla Soft, Central Depository Services (CDSL), Chambal Fertilisers & Chemicals, Hindustan Copper, Indian Energy Exchange (IEX), Indian Renewable Energy Development Agency (IREDA), RBL Bank and Titagrah Rail Systems shares are banned from F&O trading on 11 June 2025. Stocks to Watch: Jubilant Pharmova's board approved the sale and transfer of its active pharmaceutical ingredients (API) business on a slump sale basis to Jubilant Biosys, a wholly-owned subsidiary. The API business of the company achieved turnover of Rs 609 crore, representing 8.35% of the consolidated turnover for the financial year ended 31st March 2025. Canara Bank's board has approved the capital raising plan for the financial year 2025-26 amounting upto Rs 9,500 crore by way of debt instruments (Additional Tier I/Tier II Bonds). Torrent Power's wholly owned subsidiary, Torrent Green Energy has emerged as successful bidder under competitive bidding and has received letter of award from Solar Energy Corporation of India (SECI) on June 11, 2025 for setting up of 300 MW Wind power project under Wind Tranche-XVIII. The estimated investment for the project is Rs 2,650 crore. DCM Shriram's board has approved signing of a definitive agreement to acquire a 100% stake in wholly owned subsidiary, Hindusthan Speciality Chemicals for Rs 375 crore, to enter into Epoxy & Advanced Materials space, as a downstream integration of Epichlorohydrin (ECH). Dixon Technologies (India) has executed a joint venture agreement with Signify to enable formation of a joint venture company in India to carry on the OEM business of lighting products and accessories. The shareholding of the JV Co. will be held in equal proportion (50:50) by the Company and Signify CSB Bank announced that Reserve Bank of India (RBI) has approved the reappointment of Pralay Mondal as managing director & CEO of the bank for a period of three years with effect from September 15, 2025.Powered by Capital Market - Live

Revenue from operations increased 9.7% to Rs 1,915.80 crore in Q4 FY25. The company reported pre-tax profit of Rs 206 crore in Q4 FY25 as against pre-tax loss of Rs 53.70 crore in Q4 FY24. EBITDA jumped 23% to Rs 357 crore during the quarter compared with Rs 289 crore in Q4 FY24. EBITDA margin expanded 210 bps to 18.4% in Q4 FY25 as against 16.3% in Q4 FY24. In Q4 FY25, radiopharmaceuticals revenue grew by 15% YoY to Rs 296 crore, while revenue from radio pharmacy increased 7% YoY to Rs 600 crore in Q4 FY25. Revenue from Allergy Immunotherapy rose 2% YoY to Rs 192 crore and CDMO sterile injectables grew by 31% YoY to Rs 340 crore during the quarter . Contract research, development and manufacturing organisation (CRDMO) revenue stood at Rs 338 crore in Q4 FY25, up 19.86% as against with Rs 282 crore posted in Q4 FY24. The generics business reported revenue of Rs 157 crore in Q4 FY25, reflecting a 22% year-on-year decline. On full year basis, the company's consolidated net profit surged 988.7% to Rs 839.40 crore on 8.2% increase in revenue from operations to Rs 7192.10 crore in FY25 over FY24. On the outlook front, in the radiopharmaceuticals business, the company expects continued growth in Ruby-Fill installations. It remains on track to launch multiple new products in PET and SPECT imaging between FY27 and FY29. The dosing for the Phase 2 clinical trial of MIBG has been completed, and the data package is being prepared for submission to the US FDA by the second half of FY26. On the therapeutic front, over 10 new products are expected to be commercially available starting in 2029, supporting the expansion of the PET imaging industry. The proposed investment in six radiopharmacies is progressing, with commercial operations expected to begin from FY28 onwards. In the Allergy Immunotherapy segment, the company, as the sole supplier of Venom in the US, is working to expand the market by enhancing customer awareness. Revenue continues to grow in the US allergenic extracts business, and efforts are underway to penetrate markets beyond the US. In the CDMO Sterile Injectables segment, the capacity expansion at the Spokane, Washington facility is on schedule. Line 3 and Line 4 are expected to commence commercial production in late FY26 and FY28, respectively. Peak utilisation for Line 3 is now anticipated within three years of commercial launch, ahead of the earlier estimate of four years. In the CRDMO business, the medium-term outlook continues to be positive. In the short term, the business is trying to diversify its customer base and for the medium term, it is adding 'development' capabilities in addition to research and manufacturing. In the CDMO API segment, efforts are concentrated on improving capacity utilisation through CDMO projects and custom generics manufacturing. In the Generics business, the company plans to launch six to eight products per annum in across US and non-US international markets. Export volumes to the US are being scaled up gradually and meaningfully, with increased contributions expected from contract manufacturing partners. The business aims to enhance profitability and return to growth in FY26. In the Proprietary Novel Drugs segment, interim data from the Phase 2 trial of JBI-802 is anticipated in FY26. Shyam. S. Bhartia, chairman Jubilant Pharmova and Hari S Bhartia, co-chairman & non-executive director, said, 'We are pleased to announce revenue of Rs 7,235 crore in FY25, growth of 8% over last year. We delivered robust revenue growth across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables and CRDMO businesses. EBITDA grew by 24% to Rs 1,230 crore on the back of strong operating performance across all business units. EBITDA margins for the year expanded by 220 basis points. Reported PAT grew by 1,050% to Rs 836 crore, while normalised PAT grew by 112% to Rs 415 crore on the back of improved operating performance and reduced finance cost. Net Debt / EBITDA reduced from 2.5x in Mar'24 to 1.1x in Mar'25 on the back of voluntary debt prepayment of USD 125 million in FY25. During the year, the company started distributing Pylarify, an industry leading prostate cancer diagnostic imaging agent from PET radiopharmacies, completed Media Fills on Line 3 in CDMO Sterile Injectables, added strategic capabilities in the area of Biologics and Antibody drug conjugates in Drug Discovery, reached profitability in the Generics business and dosed first patients in JBI-802 and JBI-778 clinical trials. The large innovator pharma companies, for their US requirements, are now looking to create an alternate manufacturing site in the US as a risk management measure in the event of tariff imposed by the US govt. Therefore, the company is starting to see excellent traction in the CDMO Sterile Injectable business for new lines in the Spokane facility. We expect to reach peak utilisation for Line 3 in 3 years from start of commercial production vs 4 years, expected earlier.' Meanwhile, the company's board recommended a final dividend of Rs 5 per share of Re 1 each for FY25. The dividend, if approved by the shareholders, will be paid within 30 days from the date of the Annual General Meeting. The company has fixed the record date as Friday, 25 July 2025, for the purpose of final dividend payment. Jubilant Pharmova is a globally present company engaged in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, contract research, development and manufacturing (CRDMO), generics, and proprietary novel drugs businesses.Powered by Capital Market - Live

Jubilant Pharmova has fixed 25 July 2025 as record date for final dividend payment.Powered by Capital Market - Live

Net profit of Jubilant Pharmova reported to Rs 153.60 crore in the quarter ended March 2025 as against net loss of Rs 58.60 crore during the previous quarter ended March 2024. Sales rose 9.70% to Rs 1915.80 crore in the quarter ended March 2025 as against Rs 1746.40 crore during the previous quarter ended March 2024. For the full year,net profit rose 988.72% to Rs 839.40 crore in the year ended March 2025 as against Rs 77.10 crore during the previous year ended March 2024. Sales rose 8.24% to Rs 7192.10 crore in the year ended March 2025 as against Rs 6644.80 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales1915.801746.40 10 7192.106644.80 8 OPM %18.0215.54 -16.3113.56 - PBDT304.50216.20 41 989.70721.30 37 PBT209.30115.20 82 621.10339.40 83 NP153.60-58.60 LP 839.4077.10 989 Powered by Capital Market - Live

Jubilant Pharmova announced that the Board of Directors of the Company at its meeting held on 16 May 2025, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 500%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Jubilant Pharmova will hold a meeting of the Board of Directors of the Company on 16 May 2025.Powered by Capital Market - Live

K E C International Ltd, Indian Bank, J B Chemicals & Pharmaceuticals Ltd, Birla Corporation Ltd are among the other stocks to see a surge in volumes on BSE today, 13 March 2025.Jubilant Pharmova Ltd registered volume of 47967 shares by 10:47 IST on BSE, a 4.36 fold spurt over two-week average daily volume of 10996 shares. The stock rose 0.28% to Rs.867.70. Volumes stood at 14301 shares in the last session.K E C International Ltd witnessed volume of 94932 shares by 10:47 IST on BSE, a 2.69 times surge over two-week average daily volume of 35267 shares. The stock dropped 4.77% to Rs.680.55. Volumes stood at 1.36 lakh shares in the last session.Indian Bank clocked volume of 56204 shares by 10:47 IST on BSE, a 2 times surge over two-week average daily volume of 28045 shares. The stock lost 0.01% to Rs.493.60. Volumes stood at 19162 shares in the last session.J B Chemicals & Pharmaceuticals Ltd notched up volume of 6934 shares by 10:47 IST on BSE, a 1.94 fold spurt over two-week average daily volume of 3576 shares. The stock rose 1.03% to Rs.1,520.15. Volumes stood at 4591 shares in the last session.Birla Corporation Ltd notched up volume of 14277 shares by 10:47 IST on BSE, a 1.89 fold spurt over two-week average daily volume of 7542 shares. The stock slipped 2.15% to Rs.1,000.25. Volumes stood at 3166 shares in the last session.Powered by Capital Market - Live

The key equity indices traded with modest gains in the morning trade, supported by softer-than-expected inflation data from both the U.S. and India, which eased investor concerns. The Nifty traded above the 22,500 level. PSU bank shares rallied after declining in the past trading session. At 10:30 IST, the barometer index, the S&P BSE Sensex, rose 257.99 points or 0.35% to 74,295.93. The Nifty 50 index added 74.50 points or 0.33% to 22,545. The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index added 0.42% and the S&P BSE Small-Cap index rose 0.40%. The market breadth was negative. On the BSE, 2,195 shares rose and 1,269 shares fell. A total of 167 shares were unchanged. Buzzing Index: The Nifty PSU Bank index jumped 1.10% to 5,822.65. The index dropped 1.08% in the past trading session. Bank of Baroda (up 2.49%), Union Bank of India (up 1.40%), Bank of India (up 1.21%), State Bank of India (up 1.15%), Punjab National Bank (up 0.87%), Punjab & Sind Bank (up 0.84%), Canara Bank (up 0.84%), UCO Bank (up 0.67%), Central Bank of India (up 0.60%) and Indian Overseas Bank (up 0.45%) advanced. Stocks in Spotlight: Jubilant Pharmova rose 0.35%. The company received an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) with voluntary action indicated (VAI) for its subsidiary's oral formulations facility in Maryland. Yatra Online rallied 3.11% after the company informed that Rohan Purshottamdas Mittal, chief financial officer (CFO) and key managerial personnel (KMP) of the company, has resigned to pursue new opportunities. Firstsource Solutions shed 0.70%. The company announced that its subsidiary, Firstsource Group, USA Inc. has incorporated a new wholly owned subsidiary (WOS), Firstsource Solutions Limited Colombia S.A.S. Powered by Capital Market - Live

The US Food and Drug Administration (USFDA) had classified the inspection as voluntary action indicated (VAI) and confirmed that the inspection is now closed. The inspection took place in January 2025. As per the company's previous disclosure on 18 April 2024, the facility is not expected to manufacture any products as it has closed manufacturing operations. Jubilant Pharmova is engaged in radiopharma, allergy immunotherapy, CDMO of sterile injectable, generics, contract research development and manufacturing (CRDMO) and proprietary novel drugs businesses. The company's consolidated net profit jumped 51% to Rs 100.90 crore during the quarter as compared with Rs 66.80 crore in Q3 FY24. Net sales increased 8.9% YoY to Rs 1,813.70 crore in Q3 FY25. The scrip rose 0.32% to Rs 868 on the BSE.Powered by Capital Market - Live

Net profit of Jubilant Pharmova rose 51.05% to Rs 100.90 crore in the quarter ended December 2024 as against Rs 66.80 crore during the previous quarter ended December 2023. Sales rose 8.92% to Rs 1813.70 crore in the quarter ended December 2024 as against Rs 1665.20 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales1813.701665.20 9 OPM %15.8313.09 - PBDT240.70195.60 23 PBT149.40101.00 48 NP100.9066.80 51 Powered by Capital Market - Live